Wuchereria bancrofti

Wuchereria bancrofti is a human parasitic worm (Filariworm) that is the major cause of lymphatic filariasis. It is one of the three parasitic worms, together with Brugia malayi and B. timori, that infect the lymphatic system to cause lymphatic filariasis. These filarial worms are spread by a variety of mosquito vector species. W. bancrofti is the most prevalent of the three and affects over 120 million people, primarily in Central Africa and the Nile delta, South and Central America, the tropical regions of Asia including southern China, and the Pacific islands.[1] If left untreated, the infection can develop into a chronic disease called Lymphatic filariasis.[2] In rare conditions, it also causes tropical eosinophilia, an asthmatic disease. No vaccine is commercially available, but high rates of cure have been achieved with various antifilarial regimens and lymphatic filariasis is the target of the WHO Global Program to Eliminate Lymphatic Filariasis with the aim to eradicate the disease as a public-health problem by 2020.[3]

Wuchereria bancrofti
Other namesroundworm
An infection in leg by W. bancrofti
SpecialtyInfectious disease
Duration2 hours
Treatmentavermectin
Medicationivermectin once annually

Signs and symptoms

The pathogenesis of W. bancrofti infection is dependent on the immune system and inflammatory responses of the host. After infection, the worms mature within 6–8 months, male and female worms mate and then release the microfilariae. These microfilariae can be released for up to 10 years.

  1. The asymptomatic phase usually consists of high microfilaremia infection, and individuals show no symptoms of being infected. This occurs due to cytokine IL-4 suppressing the activity of TH1 cells in the immune system. This can occur for years until the inflammatory reaction rises again.
  2. In the inflammatory (acute) phase, the antigens from the female adult worms elicit inflammatory responses. The worms in the lymph channels disrupt the flow of the lymph, causing lymphedema. The individual exhibits fever, chills, skin infections, painful lymph nodes, and tender skin of the lymphedematous extremity. These symptoms often lessen after 5–7 days. Other symptoms that may occur include orchitis, an inflammation of the testes, which is accompanied by painful, immediate enlargement and epididymitis (inflammation of the spermatic cord).
  3. The obstructive (chronic) phase is marked by lymph varices, lymph scrotum, hydrocele, chyluria (lymph in urine), and elephantiasis. Microfilariae are not normally present in this phase. A key feature of this phase is scar formation from affected tissue areas. Other features include thickening of the skin and elephantiasis, which develops gradually with the attack of the lymphatic system. Elephantiasis affects men mainly in the legs, arms, and scrotum. In women, the legs, arms, and breasts are affected.

Parasite

Wuchereria bancrofti
Microfilar of W. bancrofti, from a patient seen in Haiti - the thick blood smears are stained with hematoxylin
Scientific classification
Kingdom:
Animalia
Phylum:
Nematoda
Class:
Secernentea
Order:
Spirurida
Suborder:
Spirurina
Family:
Onchocercidae
Genus:
Wuchereria
Species:
W. bancrofti
Binomial name
Wuchereria bancrofti
(Cobbold, 1877) Seurat, 1921

Morphology

As a dioecious worm, W. bancrofti exhibits sexual dimorphism. The adult worm is long, cylindrical, slender, and smooth with rounded ends. It is white in colour and almost transparent. The body is quite delicate, making removing it from tissues difficult. It has a short cephalic or head region connected to the main body by a short neck, which appears as a constriction. Dark spots are dispersed nuclei throughout the body cavity, with no nuclei at the tail tip. Males and females can be differentiated by size and structure of their tail tips. The male worm is smaller, 40 mm (1.6 in) long and 100 μm (0.0039 in) wide, and features a ventrally curved tail. The tip of the tail has 15 pairs of minute caudal papillae, the sensory organs. The anal region is an elaborate structure consisting of 12 pairs of papillae, of which eight are in front and four are behind the anus. In contrast, the female is 60 millimetres (2.4 in) to 100 millimetres (3.9 in) long and 300 micrometres (0.012 in) wide, nearly three times larger in diameter than the male. Its tail gradually tapers and rounded at the tip. No additional sensory structures are seen. Its vulva lies towards the anterior region, about 0.25 mm from the head. Adult males and females are most often coiled together and are difficult to separate. Females are ovoviviparous and can produce thousands of juveniles known as microfilariae.[4]

The microfilaria is a miniature adult, and retains the egg membrane as a sheath, and is often considered an advanced embryo. It measures 280 μm long and 25 μm wide. It appears quite structureless in vivo, but histological staining makes its primitive gut, nerve ring, and muscles apparent.[5]

Lifecycle
Lifecycle of Wuchereria bancrofti

W. bancrofti carries out its lifecycle in two hosts. Humans serve as the definitive host and mosquitos as the intermediate host. The adult parasites reside in the lymphatics of the human host. They are found mostly in the afferent lymphatic channels of the lymph glands in the lower part of the body. The first-stage larvae, known as microfilariae, are present in the circulation. The microfilariae have a membrane "sheath". This sheath, along with the area in which the worms reside, makes identification of the species of microfilariae in humans easier to determine. The microfilariae are found mainly in the peripheral blood and can be found at peak amounts from 10 pm to 4 am. They migrate between the deep and the peripheral, circulation exhibiting unique diurnal periodicity. During the day, they are present in the deep veins, and during the night, they migrate to the peripheral circulation. The cause of this periodicity remains unknown, but the advantages of the microfilariae being in the peripheral blood during these hours may ensure the vector, the nighttime mosquito, will have a higher chance of transmitting them elsewhere. Physiological changes also are associated with sleeping, such as lowered body temperature, oxygen tension, and adrenal activity, and an increased carbon dioxide tension, among other physical alterations, any of which could be the signals for the rhythmic behavior of microfilarial parasites. If the hosts sleep by day and are awake at night, their periodicity is reversed. In the South Pacific, where W. bancrofti shows diurnal periodicity, it is known as periodic.

The microfilariae are transferred into a vector, which are most commonly mosquito species of the genera Culex, Anopheles, Mansonia, and Aedes. Inside the mosquito, the microfilariae mature into motile larvae called juveniles; these migrate to the labium after a period around 10 days. When the infected mosquito has its next blood meal, W. bancrofti larvae are deposited from the mouthparts onto the skin of the prospective host and migrate through microcuts in the dermis or the tract created by the proboscis into the blood stream of the new human host. The larvae move through the lymphatic system to regional lymph nodes, predominantly in the legs and genital area. The larvae develop into adult worms over the course of a year, and reach sexual maturity in the afferent lymphatic vessels. After mating, the adult female worm can produce thousands of microfilariae that migrate into the bloodstream. A mosquito vector can bite the infected human host, ingest the microfilariae, and thus repeat the lifecycle. The organism notably does not multiply within its intermediate host, the mosquito.[5][6][7]

Diagnosis

A blood smear is a simple and fairly accurate diagnostic tool, provided the blood sample is taken during the period in the day when the juveniles are in the peripheral circulation.[8] Technicians analyzing the blood smear must be able to distinguish between W. bancrofti and other parasites potentially present.

A polymerase chain reaction test can also be performed to detect a minute fraction, as little as 1 pg, of filarial DNA.[9]

Some infected people do not have microfilariae in their blood. As a result, tests aimed to detect antigens from adult worms can be used.

Ultrasonography can also be used to detect the movements and noises caused by the movement of adult worms.[10]

Dead, calcified worms can be detected by X-ray examinations.

Prevention

Prevention focuses on protecting against mosquito bites in endemic regions. Insect repellents and mosquito nets are useful to protect against mosquito bites. Public education efforts must also be made within the endemic areas of the world to successfully lower the prevalence of W. bancrofti infections.

Eradication

The WHO is coordinating an effort to eradicate filariasis. The mainstay of this programme is the mass use of antifilarial drugs on a regular basis for at least five years.

In April 2011, Sri Lanka was certified by the WHO as having eradicated this disease.

Treatment

The severe symptoms caused by the parasite can be avoided by cleansing the skin, surgery, or the use of anthelmintic drugs, such as diethylcarbamazine, ivermectin, or albendazole. The drug of choice is diethylcarbamazine, which can eliminate the microfilariae from the blood and also kill the adult worms with a dose of 6 mg/kg/day for 12 days, semiannually or annually.[11] A polytherapy treatment that includes ivermectin with diethylcarbamazine or albendazole is more effective than either drug alone.[12] Protection is similar to that of other mosquito-spread illnesses; one can use barriers both physical (a mosquito net), chemical (insect repellent), or mass chemotherapy as a method to control the spread of the disease.

Mass chemotherapy should cover the entire endemic area at the same time. This will significantly decrease the overall microfilarial titer in blood in mass, hence decreasing the transmission through mosquitoes during their subsequent bites.

Antibiotic active against the Wolbachia symbionts of the worm have been tested as treatment.[13] Wolbachia-free worms immediately become sterile, and later die prematurely.

Epidemiology

W. bancrofti is responsible for 90% of lymphatic filariasis. Recently, 120 million worldwide cases of lymphatic filariasis were estimated. W. bancrofti largely affects areas across the broad equatorial belt (Africa, the Nile Delta, Turkey, India, the East Indies, Southeast Asia, Philippines, Oceanic Islands, and parts of South America).

The mosquito vectors of W. bancrofti have a preference for human blood; humans are apparently the only animals naturally infected with W. bancrofti. No reservoir host is known,[14] and the disease could, therefore, potentially be eradicated.

History

The effects of W. bancrofti were documented early in ancient texts. Ancient Greek and Roman writers noted the similarities between the enlarged limbs and thickened, cracked skin of infected individuals to that of elephants, hence the name elephantiasis to describe the disease.

In 1862 in Paris, Jean-Nicolas Demarquay found what appeared to be nematode worms in the fluid aspirated from a hydrocele in a young man from Havana, Cuba. Unaware of this observation, three years later in Bahia, Brazil, Otto Wucherer found these same worms but this time in urine from a woman with chyluria. Ignorant of both these observations, Timothy Lewis in India in 1870 found them in the urine of an Indian with chyluria then two years later found them in blood. Some of Lewis's specimens were examined in the same year in England by George Busk who named them Filaria sanguinis hominis.[15] In 1876 and 1877, Joseph Bancroft in Brisbane, Australia found adult worms in lymphatic abscesses in patients with larvae in the blood. He sent them to Spencer Cobbold in London who named them Filaria Bancrofti. Patrick Manson in Xiamen, China (then called Amoy) made two important observations. Firstly he discovered in 1877 that if Culex quinquefasciatus and Aedes aegypti mosquitoes fed on a person with larvae (microfilariae) in the blood, they moulted twice in the insects' abdomen and became larger worms now called infective larvae. Secondly, he found in 1879 that the blood-dwelling forms had a nocturnal periodicity with large numbers appearing in the blood around midnight with minimal numbers in the middle of the day. This coincided with the biting habits of these mosquitoes. Manson surmised that infected mosquitoes drowned and infective larvae were ingested in water. In 1899, Thomas Bancroft in Brisbane fed laboratory-reared mosquitoes on a patient with microfilaraemia, kept them for 16 days, then sent some specimens to George Low in London. Low prepared histological sections of the mosquitoes and found that the larvae migrated from the abdomen to the thorax to the salivary glands then passed down the proboscis suggesting that infective larvae were injected at a subsequent mosquito bite. In 1902, Thomas Bancroft proved that this was the mode of transmission using a related worm, Dirofilaria immitis, and generated adult worms in experimentally infected dogs. In 1921, Léon Seurat erected the genus Wuchereria and placed this worm in it as Wuchereria bancrofti.[16]

W. bancrofti is speculated to have been brought to the New World by the slave trade.[17] Once it was introduced to the New World, this filarial worm disease persisted throughout the areas surrounding Charleston, South Carolina, until its sudden disappearance in the 1920s.[18]

References
  1. Melrose WD (2002). "Lymphatic filariasis: New insights into an old disease". Int J Parasitol. 32 (8): 947–60. doi:10.1016/S0020-7519(02)00062-0. PMID 12076624.
  2. "Wuchereria bancrofti: The causative agent of Bancroftian Filariasis". ww.nematodes.org. Retrieved 20 February 2014.
  3. Ramaiah, KD; Ottesen, EA (November 2014). "Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease". PLoS Neglected Tropical Diseases. 8 (11): e3319. doi:10.1371/journal.pntd.0003319. PMC 4239120. PMID 25412180.
  4. "Lymphatic Filariasis". Stanford University. Retrieved 20 February 2014.
  5. Junghanss, Jeremy Farrar, Peter J. Hotez, Thomas (2013). Manson's Tropical Diseases: Expert Consult - Online (23rd ed.). Oxford: Elsevier/Saunders. pp. e49–e52. ISBN 9780702053061.
  6. Ridley, John W. (2012). Parasitology for Medical and Clinical Laboratory Professionals. Clifton Park, N.Y.: Cengage Learning. pp. 103–104. ISBN 9781435448162.
  7. Rajan, T.V. (2008). Textbook of Medical Parasitology. BI Publications Pvt Ltd. pp. 73–77. ISBN 9788172253172.
  8. van Hoegaerden M, Ivanoff B (1986). "A rapid, simple method for isolation of viable microfilariae". Am J Trop Med Hyg. 35 (1): 148–51. doi:10.4269/ajtmh.1986.35.148. PMID 3456213.
  9. Zhong M, McCarthy J, Bierwert L, Lizotte-Waniewski M, Chanteau S, Nutman TB, Ottesen EA, Williams SA (1996). "A polymerase chain reaction assay for detection of the parasite Wuchereria bancrofti in human blood samples". Am J Trop Med Hyg. 54 (4): 357–63. doi:10.4269/ajtmh.1996.54.357. PMID 8615447.
  10. Amaral F, Dryer G, Figueredo-Silva J, Noroes J, Cavalcanti A, Samico SC, Santos A, Coutinho A (1994). "Live adult worms detected by ultrasonography in human Bancroftian filariasis". Am J Trop Med Hyg. 50 (6): 753–7. doi:10.4269/ajtmh.1994.50.753. PMID 8024070.
  11. Eberhard ML, Hightower AW, Addiss DG, Lammine PJ (1997). "Clearance of Wuchereria bancrofti antigen after treatment with diethylcarbamazine or ivermectin". Am J Trop Med Hyg. 57 (4): 483–6. doi:10.4269/ajtmh.1997.57.483. PMID 9347968.
  12. de Kraker ME, Stolk WA, van Oortmarssen GJ, Habbema JD (May 2006). "Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti". Trop Med Int Health. 11 (5): 718–28. doi:10.1111/j.1365-3156.2006.01606.x. PMID 16640625.
  13. Taylor, MJ; Makunde, WH; McGarry, HF; Turner, JD; Mand, S; Hoerauf, A (2005). "Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial". Lancet. 365 (9477): 2116–21. doi:10.1016/S0140-6736(05)66591-9. PMID 15964448.
  14. King CL, Freedman DP (2000). "Filariasis". In G.T. Strickland (ed.). Hunter's tropical medicine and emerging infectious diseases (8th ed.). Philadelphia: E.B. Saunders. pp. 740–53. ISBN 978-0-7216-6223-7.
  15. Grove, David I (1990). A history of human helminthology. Wallingford: CAB International. pp. 1–848. ISBN 0-85198-689-7.
  16. Grove, David I (2014). Tapeworms, lice and prions: a compendium of unpleasant infections. Oxford: Oxford University Press. pp. 1–602. ISBN 978-0-19-964102-4.
  17. Laurence BR (1989). "The global dispersal of bancroftian filariasis". Parasitology Today. 5 (8): 260–4. doi:10.1016/0169-4758(89)90260-3. PMID 15463229.
  18. Chernin E (1987). "The disappearance of bancroftian filariasis from Charleston, South Carolina". Am J Trop Med Hyg. 37 (1): 111–4. doi:10.4269/ajtmh.1987.37.111. PMID 3300389.
Classification
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.